Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years.

ABSTRACT:

Objective

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Although the update of the MASLD practice guidelines and the approval of Resmetirom have brought new progress in the prevention and treatment of MASLD, this disease still has not received sufficient attention and remains a major public health issue.

Methods

Age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and disability-adjusted life years (ASDR) rates of MASLD from 1990 to 2021 were extracted from the Global Burden of Disease 2021. The estimated annual percentage change was calculated using linear regression. Six time-series models were used for training and comparison, and the optimal model was selected to predict the dise

SUBMITTER: Lin Z 

PROVIDER: S-EPMC12495469 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature